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Hemoglobinopathymoglobin (HbF) expression in humans around the time of birth causes the clinical
manifestation of sickle cell and beta-thalassemia syndromes. Inhibition of HbF among cultured cells was
recently described by the adenosine derivative molecule named SQ22536. Here, a primary cell culture model
was utilized to further explore the inhibition ofHbF byadenosine derivativemolecules. SQ22536 demonstrated
down-regulation of growth and HbF expression among erythroblasts cultured from fetal and adult human
blood. The effects upon HbF were noted in a majority of cells, and quantitative PCR analysis demonstrated a
transcriptional mechanism. Screening assays demonstrated that two additional molecules named 5′-deoxy
adenosine and 2′,3′-dideoxy adenosine had effects onHbF comparable to SQ22536. Other adenosine derivative
molecules, adenosine receptor binding ligands, and cAMP-signaling regulators failed to inhibit HbF inmatched
cultures. These results suggest that structurally related ribofuranose-substituted adenosine analogues act
through an unknown mechanism to inhibit HbF expression in fetal and adult human erythroblasts.
Published by Elsevier B.V.1. Introduction
The regulation of erythroblast growth and differentiation represents
the fundamental mechanism for the vertebrate response to environ-
mental and tissue hypoxia as well as a central aspect of many disease
states that are manifested as anemia or polycythemia. In a study of large
primates, hypoxia-associated increases of erythroblast growth were
further characterized by increased HbF expression through mechanisms
that arenotwell deﬁned [1]. Physiological andpharmacological elevations
of fetal hemoglobin are associated with amelioration of symptoms in
patients with hemoglobinopathies [2–5]. Cytotoxic drugs are used to
elevate erythrocyte levels ofHbF inpatientswith hemoglobinopathies [6].
Under some conditions of stressed erythropoiesis, either signal transduc-
tion or changes in the erythroid microenvironment are hypothesized to
increase erythroblast growth and expression of HbF [1,7,8]. Several signal
transduction pathways modulate HbF, including the mitogen-activated
protein kinase (MAPK) [9,10] and cyclic nucleotide [11] cascades. Among
ex vivo assays for stressed erythropoiesis, the combination of erythro-
poietin (EPO), stem cell factor (SCF), and transforming growth factor beta
(TGF-B), herein referred to as E+S+T, is particularly robust [12].
Pancellular expression of HbF to levels above 20% of the total hemoglobin.V.produced is regularly achieved with this cytokine combination using
mobilized peripheral blood CD34+ cells from healthy adult donors.
Very recently, the adenosine derivative, Cl-IB-MECA was shown to
inhibit erythroblast growth and differentiation, mediated through G1/G0
cell cycle arrest [13]. Another adenosine derivative named SQ22536 was
additionally shown to affect erythropoiesis by inhibiting HbF expression.
Previously, SQ22536 was shown to inhibit the upregulation of gamma-
globin gene promoter activity in erythroleukemia cells by hemin [11].
SQ22536addition toprimaryerythroid cells also reversed the inductionof
gamma-globin mRNA and protein associated with hydroxyurea, sodium
butyrate, and5-azacytidine [14]. In this study, the effects of SQ22536were
further characterized in the context of erythroblast growth, and two
additional adenosine derivatives were identiﬁed as HbF inhibitors.
2. Materials and methods
2.1. Primary erythroblast cultures and analyses
Human CD34+ cells were isolated in high purity from the peripheral
blood donated by normal human volunteers after Institutional Review
Board approval. The cells were cultured in minimum Eagle's medium
(Sigma, St. Louis, MO) containing 30% fetal bovine albumin, 1% deionized
bovine serumalbumin, 40mMglutamine,1U/ml penicillin-streptomycin,
100 cM beta-mercaptoethanol, 1 cM dexamethasone and 0.3 mg/ml
holotransferrin, with 4 U/ml of EPO alone versus EPO, SCF (50 ng/ml; R&D
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reagents except fetal bovine albumin (Hyclone, Logan, UT), glutamine and
penicillin-streptomycin (both from Biosource, Rockville, MD) were
purchased from Sigma (St. Louis, MO).
Cells obtained from at least three separate donors were used for all
assays. Onday 14, aminimumof 30,000 erythroblasts (gated on size and
granularity), were analyzed using an EPICS ELITE ESP ﬂow cytometer
(Beckman Coulter, Hialeah, FL) after immunostaining with antibodies
directed against glycophorin A (GPA), CD71 (Beckman Coulter, Miami,
FL), HbF (Caltag Laboratories, Burlingame, CA) or HbA antibodies (Perkin
ElmerWallac,Norton,OH). Positive stainingwasdeﬁnedbyﬂuorescence
at levels greater than two standard deviations above the isotypic
controls. A Nucycl™ PI kit (Exalpha Biologicals, Watertown, MA) was
used for cell cycle analyses on days 7 and 14 according to the
manufacturer's protocol. Quantitative PCR for gamma- and beta-globin
mRNA content and HPLC analyses were carried out as per conditions
described previously [12]. Based upon the large number of CD34+ cells
required for this study, cells frommultiple human donors were utilized.
Due to the predicted variability in the baseline production of HbF in EPO
and E+S+T between donors, matched controls containing no adeno-
sine-related molecules were cultured simultaneously for statistical
comparison of HbF in each experiment. Statistical signiﬁcance for all
experiments was determined by Student paired t-test analyses.
2.2. Adenosine signaling and cAMP assays
The expression of adenosine receptors in the course of maturation
of hematopoietic progenitors into erythroblasts was recently reported
[13]. In order to investigate the effects of adenosine receptor agonists,
antagonists and other adenosine derivatives (Supplemental Table I),
CD34+ hematopoietic progenitor cells were cultured in EPO and E+S+
T and titrated in 2–3 log concentration ranges. Doses were selected
according to previously published reports. SQ22536, Cl-IB-MECA,
DPCPX and ZM were obtained from Tocris (Ellisville, MO, USA). The
other compounds were purchased from Sigma (St. Louis, MO, USA).
The Chemical Abstracts Service (CAS) registry or Molecular Design
Limited (MDL) numbers are provided in the table for access.
For cAMP studies, CD34+ cells from three healthy donors were
cultured in EPO for 6 days and SCF and TGF-B were added for 10 min.
and immediately harvested and kept at 4 °C. Cells were lysed and totalTable 1
Summary of adenosine derivatives with signiﬁcant effects upon HbF expression
Name
(Concentration)
Cell count (×10(6)/ml) HbF/HbF+HbA (%)
EPO E+S+T EPO E+S+T
SQ22536
0 μM 1.3±0.0 1.3±0.1 0.3±0.2 29.5±4.7
30 μM 1.1±0.0 0.7±0.1 0.1±0.0 26.3±7.4
150 μM 0.9±0.0 0.7±0.0 0.3±0.2 12.3±2.2⁎
600 μM 0.8±0.0 0.3±0.3 0.2±0.1 2.7±2.6⁎
5′-deoxy adenosine
0 μM 1.4±0.5 1.1±0.4 7.1±2.1 49.4±8.2
5 μM 1.0±0.4 1.1±0.5 7.7±2.8 40±1.6
50 μM 0.8±0.4 0.8±0.6 2.8±0.2⁎ 21.4±4.3
500 μM 0.3±0.3⁎ 0.3±0.3⁎ 1.7±0.3⁎ NA
2′,3′-dideoxy adenosine
0 μM 1.4±0.5 1.1±0.4 7.1±2.1 49.4±8.2
0.03 μM 1.1±0.7 0.9±0.1 7.1±2.5 44±1.8
0.3 μM 1.0±0.5 0.6±0.1 6.2±3.1 45.5±12
3 μM 1.0±0.5 0.6±0.1⁎ 4.8±2.2⁎ 13.1±0.3⁎
Asterisk (⁎) denotes signiﬁcance of pb0.05 when compared to the controls for each
screen. Screens were performed using cells from three separate donors, and adenosine
derivatives were added on day 0. Proliferation and HbF productionwere determined on
day 14. Differences in control levels of HbF production were due to the use of separate
donor trios for each group of screened molecules.
Fig. 1. Structural formulas of adenosine, 5′-deoxy adenosine, 2′,3′-dideoxy adenosine
and 9-(tetrahydro-2-furyl)adenine (SQ22536).cellular cAMPwas extracted according to the protocol of cAMP Biotrak
Enzyme Immunoassay kit (Amersham Biosciences, Piscataway, NJ).
Non-acetylated cAMP was assayed according to the manufacturer's
instructions. For cAMP-signaling studies, cultured cells were incu-
bated for 14 days in increasing concentrations of activators of the
adenylate cyclase pathway: forskolin (0.8 cM–20 cM) activating
adenylate cyclase, 8-pCPT-2Me cAMP (5 cM–500 cM) for EPAC-
speciﬁc Rap1 as well as 8-bromo cAMP (0.1 cM–100 cM) for PKA
activation. Inhibitors included MDL12330A (1 cM–100 cM) for
adenylate cyclase, H-89 (0.1 cM–1 cM) and KT 5720 (4 nM–400 nM)
for protein kinase A (PKA) and rolipram (1 cM–100 cM) for PDE4. All
inhibitors were purchased from Calbiochem (La Jolla, CA).
3. Results
3.1. Inhibition of HbF expression by ribofuranose-substituted adenosine
derivatives
In this study, primary human erythroblast cultures were used to
screen and compare effects of adenosine receptor agonists and
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adenylate cyclase (Supplemental Table I) for effects upon cellular
proliferation, maturation and expression of HbF. The majority of the
screened adenosine derivatives had no signiﬁcant effect on HbF or
erythropoiesis. Additionally, Cl-IB MECA inhibited erythroblast
growth but had no demonstrable effect upon HbF production (data
not shown). MRS1220 and 3′-deoxy adenosine also inhibited ery-
throblast growth, but further analyses were confounded by cellular
toxicity. Among the other screened molecules, 5′-deoxy adenosine,
2′,3′-dideoxy adenosine, and SQ22536 inhibited erythroblast growth
and were additionally associated with signiﬁcant reductions in HbF
(Table 1). These three molecules are structurally related derivatives
of adenosine. As shown in Fig. 1, 5′-deoxy adenosine lacks the primary
hydroxyl group of the native ribose sugar, and 2′,3′-dideoxy adenosine
lacks both secondary hydroxyl groups. Interestingly, the structure of
SQ22536 lacks all three hydroxyl groups and the 5′ methylene moiety
leaving only a tetrahydrofuran ring conjugated to adenine.Fig. 2. Effect of SQ22536 on fetal hemoglobin expression and erythroblast proliferation.
(A) HbF expression (shown as HbF/HbF+HbA%) and (B) Cell counts (X105 per ml) of
matched cultures in EPO (dashed line) and E + S + T (solid line) in the presence of 0, 75,
150, 300 and 600 cM of SQ22536 analyzed on day 14. (C) Corresponding ﬂow
cytometric analysis of GPA (y-axis) and CD71 (x-axis) expression shown. The
percentage of dual positive cells (GPA+ CD71+) is provided in the top right corner of
each panel. Values with standard deviation bars from day 14 cultures of three separate
donors are shown. Asterisks (*) denote statistical signiﬁcance of p b0.05.
Fig. 3. SQ22536 effects in cord blood-derived erythroblasts. (A) HbF/HbF+HbA% and
(B) Cell counts (X105 per ml) frommatched cultures of cord blood CD34+ cells grown in
EPO (open bars) versus E + S + T (solid bars), with (+) and without (−) 300 cM SQ22536
for 14 days. Values with standard deviation bars from day 14 cultures of three separate
donors are shown. Asterisks (*) denote statistical signiﬁcance of pb0.05.Combined with previous reports [11,14], these data suggest that
SQ22536 acts as a general inhibitor of HbF induction by cytokine
signal transduction, hemin and cytotoxic drugs. Therefore, SQ22536
was examined in more detail to determine whether its effects are
mediated by inhibition of adenylate cyclase. Repeated titrations using
cells from three separate donors with SQ22536 (0–600 cM) produced
similar results (Figs. 2A and 2B). At 300 cM and 600 cM, SQ22536
showed a signiﬁcant inhibition of HbF with E+S+T. A signiﬁcant reduc-
tion in cell growth was also detected at the highest dose of 600 cM.
Analysis of expression of the transferrin receptor (CD71), and glyco-
phorin A (GPA) using ﬂow cytometry revealed decreased percentages of
cells expressing glycophorin A as a function of SQ22536 concentration
(Fig. 2C) indicative of decreased maturation of these cells.
To determinewhether the SQ22536 effects uponHbFwere limited to
cells fromthe adult stage of humandevelopment, additional assayswere
performed using progenitor cells cultured from human umbilical cord
blood. It was previously shown that E+S+T augments HbF production
among cord blood progenitor cells [15,16]. As shown in Fig. 3A, SQ22536
signiﬁcantly downregulates HbF production in both EPO (from 22.8±
1.2% to 5.9±1.0%, p=0.02) and E+S+T (from 52.8±7.5% to 31.8±1.8%,
p=0.02). In the absence of SQ22536, proliferation of the cord blood-
derived cells was more robust than cells from adults. With the addition
of SQ22536, such proliferationwas signiﬁcantly reduced in EPO,with no
signiﬁcant reduction in E+S+T (Fig. 3B).
3.2. SQ22536 effects upon cellular maturation and the cell cycle
Based upon the previously reported inhibition of erythropoiesis by
Cl-IB-MECA [13], detailed analyses of erythroblast maturation were
performed. Matched cultures of CD34+ cells in EPO and E+S+T from
three donors grown in the presence and absence of 300 cM SQ22536
were examined on days 0, 2, 4, 6, 8, 10, 12 and 14 (Fig 4A, 4B). Reduced
Fig. 4. SQ22536 effects on differentiation of cell types. CD34+ cells cultured in (A) EPO±
SQ22536 and (B) EST (E+S+T)±SQ22536 as examined by microscopy for changes in
morphology on culture days 0, 2, 4, 6, 8, 10, 12 and 14 (x-axis). On the y-axis, mean
percentages of cells identiﬁed as undeﬁned blasts (vertical lines), prepro/proerythro-
blasts (gray), basophilic normoblasts (slanted lines), polychromatic normoblasts
(white), and orthochromatic normoblasts (black) are represented.
Fig. 5. Cell cycle kinetics were analyzed in EPO±SQ22536 and EST(E+S+T)±SQ22536
on days 7 and 14. The percentage in each cell phase of the cycle deﬁned by propidium
iodide staining is shown on the y-axis. The cell cycle phases [sub G0-G1 (hatched), G0/
G1 (solid), S (open), and G2/M (gray)] are represented with standard deviation bars
using cells from three donors. Asterisks (⁎) denote statistical signiﬁcance of pb0.05.
Table 2
Effect of SQ22536 on gamma- and beta-globin mRNA expression in EPO and E+S+T
Day 14 EPO EPO+SQ22536 p value
Gamma-globin mRNA 165±22 1±0.4 1.7E−08
Beta-globin mRNA 4700±710 777±317 1.1E−07
Gamma+beta mRNA 4870±700 779±317 6.9E−08
Gamma/gamma+beta % 3.5±0.9 0.2±0.1 6.2E−06
Day 14 E+S+T E+S+T+SQ22536 p value
Gamma-globin mRNA 5260±2020 331±245 3.4E−05
Beta-globin mRNA 5040±1070 8130±5000 4.7E−02
Gamma+beta mRNA 10300±3050 8460±5250 4.4E−02
Gamma/gamma+beta % 49.9±4.9 3.6±0.6 1.4E−09
Using quantitative PCR, beta- and gamma-globin mRNA expression was examined in
CD34+ cells cultured in EPO and E+S+T in the presence and absence of 300 cM SQ22536
(added on day 0) for 14 days. The mean gamma-, beta- and gamma+beta-globin are shown
as mRNA copies/cell along with %gamma/gamma+beta-globin. Experiments were
performed in triplicate using cells from three separate donors. Mean values, standard
deviations, and statistical signiﬁcance (p values) are also shown for each culture condition.
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second culture week as evidenced by an increase in the percentage of
proerythroblasts (Fig. 4). Earlier, it was shown that the adenosine
derivative, Cl-IB-MECA inhibits erythropoiesis via a mechanism of G0/
G1 cell cycle arrest [13]. Therefore, cell cycle assays were performed to
determine if a similar mechanism of growth inhibition was mediated
by SQ22536 (Fig. 5). Rather than accumulation in G0/G1, the per-
centage of cells in G0/G1 was reduced in SQ22536 under all culture
conditions. On day 7, statistically signiﬁcant increases (p=0.01) in
apoptotic cells (sub G0/G1) and decreases (p=0.04) in G2/M cells were
additionally noted.
3.3. SQ22536 inhibits gamma-globin gene expression
To determine whether SQ22536 inhibited cytokine-signaled
HbF production by reducing levels of gamma-globinmRNA, quantitative
PCR assayswere performed. Table 2 shows the average expression levels
of gamma- and beta-globin genes from three separate donors.
Signiﬁcant reductions in the level of both gamma- and beta-globin
mRNA with SQ22536 were detected in the EPO controls. As shown
previously [12], cells grown in E+S+T demonstrated a highly signiﬁcant
increase in thegamma-globin expression. Theadditionof SQ22536 toE+
S+T signiﬁcantly reduced the level of gamma-globin transcripts, but
the beta-globin mRNA levels were reciprocally increased. As a result,SQ22536 was associated with signiﬁcant decreases in the fraction
of gamma globin mRNA (gamma/gamma+beta %) in both culture
conditions.
3.4. The inhibitory effects of SQ22536 upon HbF expression
Adult CD34+ cells from three donors maintained in EPO or E+S+T
with or without 300 cM SQ22536 were studied on day 14 (Fig. 6). Flow
cytometric analysis of cells stained for HbF revealed reduced expression
of HbF in the presence of SQ22536 in EPO and E+S+T. HbF-positive
cells were signiﬁcantly reduced, from 29.2±15% in EPO to 5.0±4.3% in
EPO+SQ22536 (p=0.03). The percentage of HbF-positive cells was also
reduced dramatically for E+S+T cultures supplemented with SQ22536
(E+S+T=92.6±0.6%; E+S+T+SQ22536=32.4±9.1%; p=0.003).
Fig. 6. Silencing of HbF expression in adult blood. CD34+ cells from adult blood were cultured in (A) EPO (B) EPO+SQ22536 (D) E+S+T and (E) E+S+T+SQ22536 for 14 days and the
cellular distribution of HbF (%) was determined on day 14 by ﬂow cytometric analysis. Representative scatter plots showing forward scatter (size; x-axis) versus HbF ﬂuorescence
(HbF %; y-axis). The horizontal lines in panels A, B, D, and E show the ﬂuorescence level at two standard deviations above the isotypic controls. The mean percentages of HbF-positive
cells with standard deviations for three donors are shown in the upper right corner of each scatter plot. Histogram overlays of (C) EPO and (F) E+S+T show cell count (Counts, y-axis)
versus HbF ﬂuorescence (FU, x-axis) in the absence (open) versus presence (gray) of 300 cM SQ22536.
Fig. 7. SQ22536-related signal transduction. (A) Scheme showing known activator and
inhibitors in cAMP pathway. (B) Effect of adenylate cyclase activators, inhibitors and
cAMP onHbF production. HbF production of cells cultured in EPO (dotted line) and E+S+
T (solid line) were analyzed by HPLC. Dose–response curves of HbF/HbF+HbA% are
represented for cAMP (brown),MDL (aquamarine), forskolin (purple), H-89 (orange), KT
(violet), 8Me-cAMP (green) and rolipram (blue). The concentration ranges are described
in the Materials and methods section. Values with standard deviation bars from day 14
cultures of three separate donors are shown.
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SQ22536 is a known inhibitor of adenylate cyclase in other cell
culture models [17–19]. Therefore, we investigated if the inhibition of
HbF in human erythroblasts by SQ22536 in this culturemodel involved
recognized elements of the adenylate cyclase pathway (Fig 7A). Explo-
ring the cAMP-PKA pathway using inhibitors, H-89 and KT5270, we
found that cytokine-induced HbF augmentation was not altered
(Fig. 7B). Neither EPAC activation by 8-pCPT-2Me nor blocking the
breakdown of cAMP by PDE4 using rolipram provided further modu-
lation of HbF. MDL12330A is another adenylate cyclase inhibitor
(structurally unrelated to SQ22536), but it failed to inhibit HbF
expression. The effects of SQ22536 and forskolin on cAMP production
were also examined in this experimental model (Fig. 8). As expected,
there was a rapid and signiﬁcant rise in cAMP after the addition of
20 cM forskolin, and signiﬁcant decrease when SQ22536 was added
with forskolin. Despite this clear effect upon cAMP in erythroblasts,
forskolin slightly decreased HbF when added for the entire 14 day
culture period in EPO or E+S+T. When SQ22536 and forskolin were
both added to E+S+T cultures, a signiﬁcant reduction in HbF was also
detected (Fig. 8D).
4. Discussion
Recent reports demonstrated the potential for adenosine deriva-
tive molecules to regulate erythropoiesis and hemoglobin expression
[11,13]. Here, screening assays were performed to show that three
structurally related adenosine derivatives act by inhibiting erythro-
blast growth and HbF expression. Structure activity relationship
analysis of ligands related to both SQ22536 and adenosine revealed a
proﬁle that can modestly be correlated to the degree of hydroxylation
of the ribofuranosemoiety of the adenosine chemical structure. While
5′-deoxy adenosine retains two of the native hydroxyl groups, 2′,3′-
dideoxy adenosine is devoid of two hydroxyl groups. On the other
hand, SQ22536 lacks the hydroxyl groups and the 5′ methylene
moiety. The changes in HbF-related activity in relation to these hy-
droxyl groups may be relevant for further investigations of the under-
lying molecular mechanism as well as the identiﬁcation of other
structurally related HbF inhibitors. The potent inhibition of HbF and
absence of G0/G1 cell cycle arrest also suggest that SQ22536 and Cl-IB-
MECA affect erythropoiesis through distinct mechanisms.
Fig. 8. Combined effects of SQ22536 and forskolin upon cAMP and HbF in human CD34+ cells. (A) Cells were cultured in EPO for 6 days prior to the addition of SCF (50 ng/ml), TGF-B
(1.25 ng/ml), SQ22536 (300 μM), and forskolin (20 μM). Cellular cAMP (fmol) was assayed at 0 (white), 10 (hatched) and 30 (gray) min. (B) Corresponding results in E + S + T shown.
Data are mean values of triplicate analyses with standard deviation bars. (C) For comparison, HbF levels were measured with cells cultured for 14 days in , EPO supplemented with
SQ22536 (300 μM) shown as black bars, versus EPO supplemented with SQ22536 (300 μM) and forskolin(20 μM) shown as white bars. (D) Corresponding HbF results in E + S + T
cultures. Data are from triplicate donor experiments with mean values and standard deviation bars shown. Asterisks (*) denote statistical signiﬁcance of pb0.05. Abbreviations: SQ:
SQ22536, EST: E+S+T. Forsk: forskolin.
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occurred under all cytokine-supplemented culture conditions, and
among erythroblasts from cord as well as adult blood. A statistically
signiﬁcant reduction of HbF was not detected by bulk assay (Table 1)
in EPO-supplemented cultures of adult cells, evidently due to the
lower level of HbF in those cells at baseline. However, the reduced
distribution of HbF-containing adult cells and the reduction in
gamma-globinmRNA suggest that the SQ22536 inhibition or silencing
of HbF occurs even when the total amount of HbF in each cell is low.
The results further suggest that the SQ22536 effects are not limited to
those experimental models, but extend also to cytokine-mediated HbF
induction and HbF production in fetal erythroblasts (cord blood).
Hence, these combined results suggest that SQ22536 is associated
with inhibition of gamma-globin transcription and HbF expression
regardless of the biological setting (hemin, cytotoxic drugs, cytokines
and development).
The quantitative PCR assays further demonstrate that HbF inhi-
bition occurs at the level of gamma-globin transcription. This result
is consistent with the ability of SQ22536 to inhibit gamma-globin
gene promoter activity in erythroleukemia cells [11]. SQ22536, 2′,3′-
dideoxy adenosine, and 5′-deoxy adenosine are all known inhibitors
of adenylate cyclase [17]. SQ22536 affects the particulate, but not
soluble isoform of the enzyme [19]. Despite the assumption that
inhibition of HbF expression was likely being mediated by a
mechanism involving adenylate cyclase, we were unable to demon-
strate that cAMP itself or other elements of the cAMP-signaling
pathway were effectors of HbF expression. Instead, dissection of
the adenylate cyclase-cAMP-PKA pathway with multiple activating
and inhibiting components of this signaling module suggested a lack
of association between cAMP signaling and HbF. MDL12330A was
also screened as a separate adenylate cyclase inhibitor predicted to
lower intracellular cAMP [20], but that molecule had no signiﬁcant
effect upon HbF expression. MDL12330A is not structurally related toadenosine. In addition, erythroblast cAMP was clearly increased
by forskolin in the absence of any signiﬁcant changes in HbF.
Differences between the results reported here and elsewhere [21]
may reﬂect the source of erythroid progenitor cells or culture
conditions, and strongly suggest that gamma-globin gene and protein
expression may be inﬂuenced by more than one signal transduction
pathway.
The clinical manifestation of all sickle cell and beta-thalassemia
syndromes begins with HbF silencing during early post-natal life.
Among all the physiological changes associated with birth, it is
possible that inspired oxygen is the initial signal for decreased levels
of erythropoiesis and silencing of fetal hemoglobin expression during
post-natal human life. HbF down-regulation begins in the fetus, but
silencing is almost completely restricted to extra-uterine life [22]. By
the age of six months, silencing is nearly complete in healthy infants.
Perinatal HbF expression is increased by hypoxia [23]. Several struc-
turally related adenosine derivative molecules were shown here to
inhibit HbF expression ex vivo through a mechanism that appears
distinct from adenylate cyclase and cAMP signal transduction. As such,
the data add support to the notion that small molecules may serve
some role in HbF silencing in vivo, and support further investigation in
this area of research.
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